Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database
BMJ2009Vol. 339(dec03 1), pp. b4731–b4731
Citations Over TimeTop 1% of 2009 papers
Ioanna Tzoulaki, Mariam Molokhia, Vasa Ćurčin, Mark P. Little, Christopher Millett, A. Ng, Robert I. Hughes, Kamlesh Khunti, Martin R. Wilkins, Azeem Majeed, Paul Elliott
Abstract
Our findings suggest a relatively unfavourable risk profile of sulphonylureas compared with metformin for all outcomes examined. Pioglitazone was associated with reduced all cause mortality compared with metformin. Pioglitazone also had a favourable risk profile compared with rosiglitazone; although this requires replication in other studies, it may have implications for prescribing within this class of drugs.
Related Papers
- → Rosiglitazone and Pioglitazone for the Treatment of Alzheimer's Disease(2011)120 cited
- → Clinical trials with thiazolidinediones in subjects with Type 2 diabetes – is pioglitazone any different from rosiglitazone?(2008)28 cited
- → Pioglitazone vs. Rosiglitazone in Older Patients with Type 2 Diabetes(2009)
- The comparison study of pioglitazone and rosiglitazone on type 2 diabetes with hyperlipemia(2009)
- → Cardiovascular safety of rosiglitazone and pioglitazone(2015)